Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

Randomised, quadruple-blind, parallel-group proof-of-concept trial (n=15) comparing IV ketamine infusions versus midazolam, both interleaved with bi-frontal brief-pulse ECT, in patients with treatment-resistant depression.

Primary hypotheses are that ketamine+ECT will produce greater clinical improvement than midazolam+ECT and will attenuate cognitive side effects; outcomes include depression severity, cognitive assessments, and safety measures.